Core Insights - Kestra Medical Technologies presented new real-world data on the ASSURE Wearable Cardioverter Defibrillator (WCD) at the Heart Rhythm 2025 conference, highlighting its effectiveness in community-based care settings [1][2][3] Group 1: Study Findings - The study demonstrated high patient compliance with a median daily wear time of 23.3 hours, indicating sustained usage beyond 90 days, which is crucial for protecting patients at risk of sudden cardiac death [3][4] - Ventricular arrhythmias were detected in 4% of patients, emphasizing the importance of real-time monitoring and early intervention in a predominantly primary prevention population [4] - The APP-driven care model effectively delivered WCD therapy in accordance with guideline-based recommendations, ensuring that all indicated patients received appropriate care [5] Group 2: Company Mission and Vision - Kestra aims to expand access to intelligent, connected cardiac recovery solutions across all levels of care, marking a significant milestone in its mission [6] - The company focuses on transforming patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies [7]
Kestra Showcases Real-World Outcomes for ASSURE WCD at Heart Rhythm 2025